Tracey G. Simon

7.9k total citations · 7 hit papers
109 papers, 5.0k citations indexed

About

Tracey G. Simon is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Tracey G. Simon has authored 109 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Epidemiology, 51 papers in Hepatology and 17 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Tracey G. Simon's work include Liver Disease Diagnosis and Treatment (87 papers), Liver Disease and Transplantation (29 papers) and Hepatitis C virus research (20 papers). Tracey G. Simon is often cited by papers focused on Liver Disease Diagnosis and Treatment (87 papers), Liver Disease and Transplantation (29 papers) and Hepatitis C virus research (20 papers). Tracey G. Simon collaborates with scholars based in United States, Sweden and China. Tracey G. Simon's co-authors include Jonas F. Ludvigsson, Björn Roelstraete, Hannes Hagström, Raymond T. Chung, Kathleen E. Corey, Hamed Khalili, Andrew T. Chan, Xuehong Zhang, Edward L. Giovannucci and Adeel A. Butt and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Tracey G. Simon

108 papers receiving 4.9k citations

Hit Papers

Mortality in biopsy-confirmed nonalcoholic fatty liver di... 2020 2026 2022 2024 2020 2021 2020 2021 2022 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
    2020 432 citations Tracey G. Simon, Björn Roelstraete et al. Gut profile →
  2. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
    2021 379 citations Alessandro Mantovani, Kathleen E. Corey et al. profile →
  3. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
    2020 216 citations Tracey G. Simon, Raymond T. Chung et al. profile →
  4. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort
    2021 201 citations Tracey G. Simon, Björn Roelstraete et al. Gut profile →
  5. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma
    2022 155 citations Tracey G. Simon et al. profile →
  6. Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
    2024 48 citations Tracey G. Simon, Robert M. Wilechansky et al. profile →
  7. AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals
    2025 15 citations Faisal S. Ali, Rubén Hernáez et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tracey G. Simon United States 38 3.6k 2.0k 1.2k 686 556 109 5.0k
Kathleen E. Corey United States 44 4.8k 1.3× 2.5k 1.2× 1.9k 1.6× 1.3k 1.9× 962 1.7× 167 7.0k
Mark Muthiah Singapore 32 2.5k 0.7× 1.2k 0.6× 1.0k 0.9× 636 0.9× 536 1.0× 184 4.1k
Alina M. Allen United States 32 3.8k 1.0× 2.3k 1.1× 1.2k 1.0× 837 1.2× 431 0.8× 107 4.5k
Yuichiro Eguchi Japan 40 4.8k 1.3× 3.0k 1.5× 1.6k 1.4× 1.0k 1.5× 981 1.8× 178 6.7k
Stuart McPherson United Kingdom 32 5.3k 1.5× 3.2k 1.6× 1.9k 1.6× 902 1.3× 522 0.9× 139 6.2k
Luigi Elio Adinolfi Italy 43 4.5k 1.3× 3.8k 1.9× 1.0k 0.9× 547 0.8× 633 1.1× 139 6.4k
Bilal Hameed United States 24 4.1k 1.1× 2.5k 1.2× 1.3k 1.1× 1.2k 1.8× 857 1.5× 70 5.7k
Andreas Geier Germany 41 3.5k 1.0× 2.4k 1.2× 849 0.7× 1.8k 2.6× 1.4k 2.5× 209 6.7k
George Cholankeril United States 31 3.0k 0.8× 1.8k 0.9× 874 0.7× 604 0.9× 373 0.7× 145 4.0k
Norberto C. Chávez‐Tapia Mexico 36 2.9k 0.8× 1.7k 0.8× 912 0.8× 1.2k 1.7× 703 1.3× 194 4.7k

Countries citing papers authored by Tracey G. Simon

Since Specialization
Citations

This map shows the geographic impact of Tracey G. Simon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tracey G. Simon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tracey G. Simon more than expected).

Fields of papers citing papers by Tracey G. Simon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tracey G. Simon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tracey G. Simon. The network helps show where Tracey G. Simon may publish in the future.

Co-authorship network of co-authors of Tracey G. Simon

This figure shows the co-authorship network connecting the top 25 collaborators of Tracey G. Simon. A scholar is included among the top collaborators of Tracey G. Simon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tracey G. Simon. Tracey G. Simon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Choi, Jonggi, Tushar Kamath, Vy H. Nguyen, et al.. (2025). GLP ‐ 1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching. Liver International. 45(12). e70447–e70447.
2.
Ali, Faisal S., Rubén Hernáez, Daniel Q. Huang, et al.. (2025). AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals. Gastroenterology. 168(2). 267–284. 15 indexed citations breakdown →
3.
Sherman, Marc S., Eric M. Przybyszewski, Robert M. Wilechansky, et al.. (2024). A natural language processing algorithm accurately classifies steatotic liver disease pathology to estimate the risk of cirrhosis. Hepatology Communications. 8(4). 2 indexed citations
4.
Zhang, Xinyuan, Longgang Zhao, Long Ngo, et al.. (2024). Prediagnostic plasma proteomics profile for hepatocellular carcinoma. JNCI Journal of the National Cancer Institute. 116(8). 1343–1355. 3 indexed citations
5.
Simon, Tracey G., et al.. (2023). Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease. 27(2). 251–273. 6 indexed citations
6.
Ebrahimi, Fahim, Tracey G. Simon, Hannes Hagström, et al.. (2023). Antibiotic use and development of nonalcoholic fatty liver disease: A population‐based case–control study. Liver International. 43(10). 2186–2197. 8 indexed citations
7.
Simon, Tracey G., et al.. (2023). Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets. Clinical Epidemiology. Volume 15. 349–362. 1 indexed citations
8.
Ebrahimi, Fahim, Tracey G. Simon, Hannes Hagström, et al.. (2023). Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease – A Population-based Cohort Study. Clinical Gastroenterology and Hepatology. 21(13). 3346–3355.e19. 15 indexed citations
9.
Simon, Tracey G., Sebastian Schneeweiß, Daniel E. Singer, Sushama Kattinakere Sreedhara, & Kueiyu Joshua Lin. (2023). Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation. Journal of the American Heart Association. 12(3). e026863–e026863. 13 indexed citations
10.
Mantovani, Alessandro, Christopher D. Byrne, Giovanni Benfari, et al.. (2022). Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease. Journal of the American College of Cardiology. 79(2). 180–191. 78 indexed citations
11.
Simon, Tracey G., Mi Na Kim, Xing Liu, et al.. (2021). Adiposity, Adulthood Weight Change, and Risk of Incident Hepatocellular Carcinoma. Cancer Prevention Research. 14(10). 945–954. 10 indexed citations
12.
Haas, Mary E., James P. Pirruccello, Sam Friedman, et al.. (2021). Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genomics. 1(3). 100066–100066. 55 indexed citations
13.
Kim, Mi Na, Chun‐Han Lo, Kathleen E. Corey, et al.. (2021). Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: Evidence from mediation analysis. Clinical Nutrition. 41(2). 356–364. 34 indexed citations
14.
Yang, Wanshui, Yanan Ma, Tracey G. Simon, et al.. (2020). Physical Activity and Risk of Hepatocellular Carcinoma Among U.S. Men and Women. Cancer Prevention Research. 13(8). 707–714. 8 indexed citations
15.
Osganian, Stephanie A., et al.. (2020). Epoxygenase-Derived Epoxyeicosatrienoic Acid Mediators Are Associated With Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Fibrosis. Gastroenterology. 159(6). 2232–2234.e4. 16 indexed citations
16.
Sui, Jing, Wanshui Yang, Yanan Ma, et al.. (2019). A Prospective Study of Nut Consumption and Risk of Primary Hepatocellular Carcinoma in the U.S. Women and Men. Cancer Prevention Research. 12(6). 367–374. 20 indexed citations
17.
Simon, Tracey G., Kathleen E. Corey, Christopher P. Cannon, et al.. (2018). The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology. 270. 245–252. 51 indexed citations
18.
Simon, Tracey G., Daniel Bamira, Raymond T. Chung, Rory B. Weiner, & Kathleen E. Corey. (2017). Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. Obesity. 25(8). 1313–1316. 67 indexed citations
19.
Simon, Tracey G., Kathleen E. Corey, Raymond T. Chung, & Robert P. Giugliano. (2016). Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Digestive Diseases and Sciences. 61(12). 3425–3435. 12 indexed citations
20.
Herkel, Johannes, Albert J. Czaja, Stephan Kanzler, et al.. (2002). Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 51(2). 259–264. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kathleen E. Corey Breakdown of academic impact, for papers by Mark Muthiah Breakdown of academic impact, for papers by Alina M. Allen Breakdown of academic impact, for papers by Yuichiro Eguchi Breakdown of academic impact, for papers by Stuart McPherson Breakdown of academic impact, for papers by Luigi Elio Adinolfi Breakdown of academic impact, for papers by Bilal Hameed Breakdown of academic impact, for papers by Andreas Geier Breakdown of academic impact, for papers by George Cholankeril Breakdown of academic impact, for papers by Norberto C. Chávez‐Tapia
Rankless by CCL
2026